WntResearch recently announced that the Spanish authorities have approved the revised study plan for the phase II study NeoFox with the drug candidate Foxy-5 in colon cancer. The company has introduced new endpoints on the primary tumour already at the patients' surgery, which enables significantly earlier data readout and thus cost and time savings. BioStock talked to CEO Pernilla Sandwall about the benefits of the new study design.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/07/new-study-plan-approved-for-wntresearchs-phase-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/wntresearch/r/biostock-new-study-plan-approved-for-wntresearch-s-phase-ii-study,c3805111

(c) 2023 Cision. All rights reserved., source Press Releases - English